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Abstract: Adrenomedullin is a highly conserved peptide implicated in a variety of physiological processes ranging from 
pregnancy and embryonic development to tumor progression. This review highlights past and present studies that have 
contributed to our current appreciation of the important roles adrenomedullin plays in both normal and disease conditions. 
We provide a particular emphasis on the functions of adrenomedullin in vascular endothelial cells and how experimental 
approaches in genetic mouse models have helped to drive the field forward. 
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INTRODUCTION 
The Multifunctional Adrenomedullin Peptide 
 Adrenomedullin  (gene=Adm; protein=AM) is a highly 
conserved multifunctional peptide that is implicated in a 
wide variety of physiological processes including angio- 
genesis and cardiovascular homeostasis [1]. For over a 
decade, the association of ~2-fold elevations in plasma levels 
of AM peptide with a wide variety of cardiovascular disease 
conditions has prompted intense inquiry into understanding 
the functions and roles of AM in human disease (Fig. 1). 
Moreover, the recent development of highly precise methods 
for the quantitation of midregional proadrenomedullin (MR-
proADM) as a reliable surrogate of mature AM plasma 
levels [2], has paved the way for the introduction of AM as a 
clinically useful biomarker for the staging of adverse 
cardiovascular events, including myocardial infarction, 
sepsis and community acquired pneumonia [3-6]. While it is 
clear that AM can elicit powerful effects on vascular smooth 
muscle cells and thus acutely modulate vascular tone, 
numerous studies in the past 5 years have elucidated 
essential functions of AM on vascular endothelial cells. In 
the following sections we review the multi-faceted role of 
AM in endothelial cells during development, consider how 
perturbations in AM signaling may lead to vascular 
pathologies, and highlight recent discoveries regarding AM 
that have contributed in substantial ways to the broader field 
of vascular biology. Many of these discoveries have been 
unraveled through the use of sophisticated genetic animal 
models (Tables 1 and 2), and so we have placed a special  
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Fig. (1). Fold Change in Plasma Adrenomedullin Levels in a 
Variety of Human Conditions. Bars indicate average fold change 
in circulating AM levels in various disease categories or conditions 
based on published human clinical data. The dashed horizontal line 
at 2.33 represents the average fold increase in plasma AM levels 
across all conditions depicted. Number above each bar indicates the 
number of published observations assessing plasma AM levels in 
each category. The clinical papers that were used for our analysis 
are listed according to the following broad categories: cancer [117-
122], cardiovascular [4, 117, 119, 123-150], hepatic and renal [130, 
131, 133, 134, 151-162], pulmonary [6, 131, 163-168], infectious  
& autoimmune [169-175], normal pregnancy [63, 64, 66-67, 176-
180], and pregnancy complications [63, 67, 180-192]. 
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emphasis on describing the merits and shortcomings of these 
approaches and also highlighting current questions that are 
of predominant interest to the field today. 
Adrenomedullin GPCR-Mediated Signaling in 
Endothelial Cells 
  G-protein coupled receptors (GPCRs) are widely 
expressed proteins that span the cell membrane 7 times and 
respond to a variety of stimuli including peptides, proteins, 
small organic compounds, lipids, amino acids, and cations. 
AM binds and signals through the GPCR calcitonin receptor-
like receptor (gene=Calcrl; protein=CLR). The discovery of 
a novel class of GPCR associated proteins called receptor 
activity-modifying proteins (gene=Ramp; protein=RAMP) 
[7] provided insight into how GPCRs signal. The RAMPs 
are single-pass transmembrane accessory proteins that 
Table 1.  Gene Targeted Mouse Models for Studying Adrenomedullin Signaling 
Mouse Model 
Development or 
Adulthood  Result  Reference 
Adm
-/-  Development   
-Embryonic lethal (e14.5), edema, smaller hearts, reduced myocyte proliferation and 
increased apoptosis, increased left ventricle trabecularization, thinner aorta and carotid 
artery walls, increased vascular permeability, hypoplastic jugular lymph sac   [22,30-32]  
Adm
+/-  Adulthood 
-Pregnancy: Disrupted fertility, placentation, and fetal growth  
-Cardiovascular: Increased damage including hypertrophy, reactive oxygen species (ROS), 
and fibrosis -Liver cold injury: increased apoptosis of the sinusoidal endothelial cells   [32,70,81,90]  
Adm
fl/fl/Tubulin T-1-Cre
+   Adulthood   -High anxiety, hyeractive, impaired motor coordination   [116]  
Calcrl
-/-   Development   -Embryonic lethal (e13.5), similar phenotype as Adm
-/- mice   [22,33]  
Calcrl
LoxP/-/Tie2Cre
+   Development   -Embryonic lethal (e16.5) and recapitulation of Adm
-/-, Calcrl
-/-, and Ramp2
-/- phenotype   [22]  
Ramp2
-/- and  
Ramp2
fl/fl/CAG-Cre
+  Development   -Embryonic lethal (e15.5), similar phenotype as Adm
-/- mice   [18,22,34]  
Ramp2
+/-  Adulthood 
-Increased vascular permeability and decreased neovascularization  
-Liver cold injury: increased apoptosis of the sinusoidal endothelial cells   [18,90] 
PAM
-/-  Development   
-Embryonic lethal (e14.5) and phenocopy of Adm
-/-, Calcrl
-/-, and Ramp2
-/- mice due to loss 
of amidation of AM peptide  [35]  
Adrenomedullin (Adm); Calcitonin receptor-like receptor (Calcrl); Receptor activity modifying protein (RAMP); Peptidylglycine alpha-amidating monooxygenase (PAM) 
Table 2.  Vascular Assays for Studying Adrenomedullin Function 
Assay Result  Reference 
Atherogenic Model  
-Atherogenic diet and AM treatment in ApoE
-/- mice resulted in reduced formation of atherosclerotic 
lesions  [87] 
Tail microlymphography   -AM injected mice showed reduced permeability of the dermal lymphatic capillaries  [25] 
Matrigel plug  -AM increased vascular regeneration -Ramp2
+/- mice exhibited reduced neovascularization   [12,13,18] 
Aortic ring  -Ramp2
+/- mice exhibited reduced neovascularization in response to growth factor stimulation   [18] 
AngII/high-salt  
AM
+/- mice exhibited increased reactive oxygen species (ROS), vascular fibrosis, and intimal 
thickening  [39] 
Prolonged mechanical ventilation  -AM treatment reduced lung vascular permeability resulting from ventilator use  [21] 
Chronic cerebral hypofusion   -AM promoted arteriogenesis and angiogenesis  [98] 
Hind-limb ischemia 
-AM promotes endothelial cell proliferation and capillary formation -Adm
+/- mice showed reduced 
blood flow and capillary development  [58] 
Wound healing (Pressure Ulcer -
Ischemia reperfusion model)  -AM reduced wound area and increased angiogenesis and lymphangiogenesis   [99] 
Tail lymphedema   -AM improved lymphedema and increased number of lymph and blood vessels  [11] 
Tumor xenografts   -Blocking AM signaling results in reduced vascular development  [58, 114, 115] 230    Current Hypertension Reviews, 2011, Vol. 7, No. 4  Karpinich et al. 
regulate the translocation of GPCRs to the plasma membrane 
as well as provide ligand specificity to these receptors. The 
tissue specific and temporal expression pattern of RAMPs 
determines the responsiveness of GPCRs to particular 
ligands. For example, AM binds to the CLR receptor when 
CLR is associated with either RAMP2 or RAMP3. However, 
co-expression of CLR with RAMP1 changes the ligand 
specificity to another potent vasodilator called calcitonin 
gene-related peptide (CGRP), a related family member of the 
AM peptide. The ability of CLR to bind multiple ligands 
provides a unique mechanism by which the receptor can 
initiate a variety of signaling pathways. Since the AM 
receptor CLR and the 3 mammalian RAMPs are highly 
expressed in the vasculature, this cell signaling paradigm is 
being intensely investigated to determine how it can be 
exploited for the potential treatment of conditions such as 
pulmonary hypertension [8], cardiovascular disorders [9], 
and the inhibition of cancer metastasis [10]. 
  The binding of AM to its receptor CLR results in a 
myriad of downstream effects including modulation of 
endothelial cell survival, proliferation, and vessel permeability. 
For example, AM-induced proliferation and migration of 
lymphatic endothelial cells is mediated in part by cAMP   
and downstream MEK/ERK pathways [11]. Similar results 
were shown using cultured human umbilical vein endothelial 
cells (HUVECs). AM-mediated induction of HUVEC 
proliferation and migration through activation of PKA, 
PI3K, and focal adhesion kinase were observed and then 
further substantiated in whole animal studies [12, 13]. AM 
induced the proliferation and migration of cultured HUVECs 
[12] and numerous studies have shown a direct role for AM 
in endothelial growth and survival [14-16]. 
 Using  in vitro experiments, AM was found to regulate 
the permeability and migration of HUVECs [17]. Previous 
studies indicated that adult Ramp2
+/-  mice had increased 
vascular permeability and overexpression of Ramp2 in BECs 
resulted in reduced permeability [18]. AM also reduces the 
permeability of HUVECs and pulmonary artery endothelial 
cells treated with permeabilizing agents including hydrogen 
peroxide and thrombin [19]. AM has been shown to regulate 
the transport of molecules across the blood brain barrier in 
cerebral endothelial cells by modulating permeability [20]. 
In cerebral endothelial cells, AM regulated various functions 
of the blood brain barrier including increasing trans- 
endothelial electrical resistance, reducing fluid-phase 
endocytosis, and reducing permeability for sodium 
fluorescein which indicate that the cerebral endothelial cell 
junctions are tightened by AM [20]. Also in an in vivo 
model, AM treatment reduced lung vascular permeability 
resulting from ventilator use in a mouse model where 
prolonged mechanical ventilation was administered [21]. 
Overall, these data provide evidence for the role of AM as a 
junctional tightening factor to help regulate endothelial cell 
permeability.  
  Although AM functions to promote endothelial cell 
growth and proliferation in both the blood and lymphatic   
 
vasculatures, Fritz-Six et al. have shown that there is an 
enhanced effect of AM on lymphatic endothelial cells 
(LECs) as compared to blood endothelial cells (BECs) [22]. 
This biological distinction in AM function is based upon the 
finding that LECs are enriched in the expression of AM and 
its receptor components, Calcrl and Ramp2 [22-24]. This 
increase in Calcrl expression is mediated in part by 
induction of the transcriptional regulator of lymphatic 
specification, Prox1 [22]. It is therefore not surprising that 
loss of any component of the AM signaling axis (Adm, 
Calcrl, or Ramp2) results in embryonic lethality associated 
with profound lymphatic vascular defects [22]. Furthermore, 
several  in vitro and in vivo experiments reveal that AM 
controls lymphatic permeability and flow through 
reorganization of junctional proteins ZO-1 and an adherens 
protein VE-Cadherin, independent of changes in junctional 
protein gene expression [25]. Administration of AM to a 
monolayer of LECs resulted in tightening of the lymphatic 
endothelial barrier by reorganization of a tight junction 
protein at the plasma membrane to form continuous cell-cell 
contacts. Through the use of in vivo tail microlymphography, 
local administration of AM in a SvEv129/6 mouse tail 
resulted in decreased velocity of lymph uptake from the 
interstitial space and movement through the lymphatic 
dermal capillaries in the tail [25]. Thus, it becomes critically 
important to consider the pleiotropic effects of AM not just 
on blood endothelial cells, but also on neighboring lymphatic 
vessels—a dynamic that may ultimately help resolve the 
complex functions of AM peptide in cardiovascular disease, 
tumor progression and inflammation.  
  While activation of GPCRs typically leads to induction 
of classical second messenger signaling systems, it is now 
appreciated that more complex levels of regulation exist [26, 
27]. Therefore, it is not surprising that pathway cross-talk is 
one mechanism through which AM modulates certain 
endothelial cell functions. For example, Yurugi-Kobayashi   
et al. describe a novel embryonic stem cell differentiation 
system to study mechanisms of arterial-venous specification. 
They demonstrated that coordinated signaling of AM/ 
cAMP, VEGF, and Notch induces arterial endothelial cell 
differentiation from vascular progenitors [28]. Furthermore, 
GPCR-induced transactivation of receptor tyrosine kinases is 
another mechanism that allows interaction between signaling 
molecules. Evidence exists that AM and VEGF pathways are 
likely to interact in endothelial cells. Although an earlier 
study claimed that AM-induced capillary tube formation   
in HUVECs was independent of VEGF activation [14], a 
more recent study by Guidolin et al. demonstrated that 
VEGFR2 inactivation inhibited AM-mediated angiogenesis 
in HUVECs [29]. This latter finding suggests that the pro-
angiogenic effects of AM require transactivation of the 
receptor tyrosine kinase VEGFR2. Although controversy 
still exists regarding the degree of cooperation between 
pathways, it is certainly intriguing to consider that regulation 
of endothelial cell biology may very likely involve 
coordination of multiple signaling molecules. We now must 
begin to unravel these complexities and elucidate whether   
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these interactions occur differentially in blood and lymphatic 
endothelial cells and identify the intermediate molecular 
players involved in pathway cross-talk in the vasculature. 
DEVELOPMENT 
Endothelial Adrenomedullin Signaling is Essential for 
Embryonic Development 
  Work by multiple independent groups has established the 
importance of AM signaling during development. The use of 
gene targeted mouse models clearly indicates that functional 
AM signaling is essential for embryonic survival. The 
genetic ablation of Adm [30-32], Calcrl [33], Ramp2 [18, 22, 
34] or the enzyme responsible for functional AM amidation, 
peptidylglycine alpha-amidating monooxygenase (PAM) [35] 
all result in midgestational lethality associated with severe 
interstitial edema and cardiovascular defects. The conserved 
phenotypes between these knockout (KO) mice is 
compelling genetic evidence that the CLR/RAMP2 complex 
is the main receptor of AM during development, and also is 
the first in vivo confirmation that RAMP2 functionally 
interacts with CLR [22]. 
  Although the overt phenotypes of these KO mice are 
conserved, the physiological cause of edema and lethality   
is still debated. One possible hypothesis is that loss of   
AM signaling causes developmental cardiac abnormalities   
that lead to heart failure, thus resulting in edema and death 
that is similar to previously characterized KO mice with 
developmental heart failure [36-38]. Supporting this line of 
thought, our lab showed that Adm
-/-, Calcrl
-/-, and Ramp2
-/- 
mice have smaller hearts due to decreased myocyte 
proliferation and increased apoptosis. Additionally, they 
have increased left ventricle trabecularization, which leads to 
decreased ventricular volume [22, 30, 33]. However, an 
alternative hypothesis is that vascular defects are responsible 
for the phenotypes, since Adm [30], Calcrl [33], and Ramp2 
[18] are abundantly expressed in the developing endothelium 
and vascular smooth muscle cells (vSMC). To help resolve 
between the two hypotheses, we generated an endothelial-
specific Calcrl
-/- mouse using a Tie2 promoter to drive Cre 
recombinase expression which recapitulated the phenotype 
observed in global KO mice [22], indicating that AM 
signaling in endothelial cells is essential for embryonic 
development. A remaining caveat to this conclusion is   
the fact that Tie2-Cre mediated excision also occurs in 
developing endocardial cells. Therefore, to definitively 
determine if cardiac abnormalities contribute to this 
phenotype the reverse experiment using Cre lines specific to 
cardiac myocytes would be beneficial.  
  Although vascular defects are responsible for the edema 
in these KO mice, it remained unclear whether defects in the 
blood or lymphatic endothelium were the principle cause of 
the phenotypes. Given the role of AM in regulating vascular 
permeability, it seems reasonable that loss of AM signaling 
could lead to increased vascular permeability and a resulting 
build up of interstitial fluid. In support of this idea, the KO 
mice have thinner aorta and carotid artery walls due to a 
decrease in vSMC proliferation [18, 30, 33], although the 
endothelium lining the aorta appeared to be normal [33]. 
There are reported abnormalities in endothelial basement 
membranes and a down-regulation of junctional proteins in 
Adm
-/- and Ramp2
-/- embryos that may lead to increased 
vascular permeability and hemorrhage [18, 31], but these 
phenotypes were observed in a small proportion of animals 
and not conserved in all studies. In addition, the severity of 
the edema and their survival beyond e10.5 does not resonate 
with other knockout mouse models with established vascular 
permeability defects [39-41]. In contrast, the onset 
(Calcrl=E13.5, Adm=E14.5, Ramp2=E15.5) and severity of 
the phenotype closely resembles other genetic mouse models 
that delete genes essential for lymphatic development, 
including Prox1 [42], Sox18 [43], and Vegfc [44]. 
  To determine whether lymphatic vasculature defects may 
contribute to the edema observed in AM signaling KO 
animals, we performed a comprehensive study of AM 
signaling expression and function during lymphatic vascular 
development [22]. Adm is temporally and spatially expressed 
on the endothelium of the jugular vein in a polarized fashion 
towards the budding primary lymph sac in vivo, which is 
identical to the master lymphatic regulator, Prox1 [42, 45, 
46]. Moreover, Calcrl and Ramp2 are preferentially up-
regulated in LECs, partially under the control of the 
lymphatic-specific transcriptional regulator, Prox1. While 
loss of AM signaling did not affect the differentiation and 
migration of LECs to form the primary lymph sac or dermal 
lymphatics, it did lead to a hypoplastic jugular lymph sac 
due to decreased LEC proliferation. This result indicates that 
AM signaling is essential for normal LEC proliferation in 
vivo and the KO mice develop edema due to smaller jugular 
lymphatic vessels that are unable to maintain homeostatic 
fluid balance. It is also interesting to note that the jugular 
lymphatic trunk is affected by loss of AM signaling, while 
retroperitoneal and dermal lymphatic vessels appear normal. 
This indicates that there are different cellular mechanisms 
regulating different lymphatic beds during development. 
However, AM does appear to be an essential growth factor 
for developing LECs in vivo [22]. Thus, it is most likely that 
a combination of both blood and lymphatic defects leads to 
the edema and lethality in the KO mice given the integrated 
physiology between the two vasculatures. However, more 
specialized genetic assays are required to resolve the relative 
contributions of each vasculature within these KO mice [47].  
  An alternative approach to assess the role of AM 
signaling in development would be to use transgenic   
mouse models that overexpress Adm,  Calcrl, or Ramp2. 
Interestingly, no developmental phenotypes have been 
reported in gain-of-function mouse models of AM signaling, 
either by vascular Adm overexpression [48] or vSMC-
specific  Ramp2 overexpression [49], though these models 
displayed adult cardiovascular phenotypes. Given the 
essential nature of AM signaling within the endothelium, it 
would be interesting to over express Calcrl or Ramp2 
specifically in the endothelium, which to our knowledge, has 
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Adrenomedullin vs. Proadrenomedullin 
  One potential caveat with the majority of Adm
-/- studies is 
that the gene targeting strategies delete the entire Adm 
coding sequence [30, 31], which results in the genetic KO of 
two functionally active peptides, AM and proadrenomedullin 
N-terminal 20 amino acid peptide (PAMP) [50]. PAMP is  
a small peptide that is produced during post-transcriptional 
splicing of preproadrenomedullin and has numerous actions 
to complement or antagonize AM signaling [50-53]. For two 
of the reported Adm deficient mouse lines, the design of the 
targeted allele could not rule out whether the observed 
phenotypes in the KO animals were due to loss of AM, 
PAMP, or both [30, 31]. This controversy was partially 
resolved using a third independent Adm
-/- mouse, which left 
PAMP intact, and illustrated that loss of AM alone was 
enough to recapitulate embryonic lethality [32]. However, 
these mice lacking only AM had a milder phenotype (less 
edema and no cardiovascular abnormalities) when compared 
to KO mice lacking both peptides. This inconsistency in 
phenotypes could be attributed to differences in mouse strain 
and/or gene targeting approach [32]. However, a more 
intriguing hypothesis, which remains to be vigorously 
experimentally addressed, is that AM and PAMP may have 
non-redundant functions during cardiovascular development 
[54]. 
Developmental Role of RAMP2 vs. RAMP3 
 While  Ramp2
-/- mice recapitulated the Adm
-/- and Calcrl
-/- 
phenotypes, it appears that RAMP3, another RAMP that 
associates with CLR and binds AM, is not essential for 
embryonic survival since Ramp3
-/- mice develop normally to 
adulthood. There also appears to be no functional 
redundancy between RAMP2 and RAMP3 in development, 
since there is no transcriptional compensatory mechanism of 
either RAMP in response to loss of the other [18, 34]. 
Although RAMP3 has been implicated in receptor 
trafficking [7, 55, 56], the functional role of the AM/CLR/ 
RAMP3 signaling complex is not well understood in vivo.  
New Developmental Insights of Adrenomedullin Pathway 
  A recent study by Nicoli et al. expanded our knowledge 
regarding the role of CLR during embryonic vascular 
development using a zebrafish model. By knocking down 
crlr they showed drastic vascular defects due to decreased 
expression of vegf. While vegf appears to be the critical 
mediator in the vascular development since overexpression 
of vegf is able to rescue the crlr knockdown phenotype, it 
still appears that crlr is essential for appropriate levels of 
vegf. This study provides in vivo evidence that crlr is 
downstream of sonic hedgehog, but upstream of vegf and 
notch signaling in arterial differentiation and development 
[57]. Modulation of vegf  levels by AM signaling were 
previously reported in mice [58] but a complete 
characterization of AM and VEGF interactions is not well 
understood. It is novel that sonic hedgehog appears to 
regulate  crlr expression and further dissection of this 
pathway in animal models would improve our understanding 
of how CLR is regulated during development. The zebrafish 
model system has recently been used to study lymphatic 
development [59-61] and it would be interesting if 
phenotypes seen in Adm
-/-, Calcrl
-/-, and Ramp2
-/- mice could 
be recapitulated in zebrafish. 
PHYSIOLOGY AND PATHOLOGY 
Adrenomedullin Signaling in Pregnancy 
  AM signaling is known to be a critical component for 
initiation and progression of normal pregnancy. By the third 
trimester of a normal pregnancy, plasma levels of AM 
increase 4- to 5-fold [62-67]. AM is highly expressed in all 
vascular tissues which include the placenta and uterus [68-
69]. Our previous studies in Adm
+/- female mice expressing 
50% less adrenomedullin revealed that there is disrupted 
fertility, placentation, uterine receptivity, and fetal growth 
resulting from reduced AM expression [70]. AM signaling 
components are also expressed in the trophoblast cells [71-
76], which take on an endothelial-like function during the 
process of decidual maternal spiral artery remodeling during 
pregnancy. The trophoblast giant cells deriving from the 
trophectoderm invade and replace the vascular wall by 
inducing a loss of endothelial cells and smooth muscle cell 
coverage to allow for higher blood flow to the fetus through 
the spiral arteries. Failure of this remodeling process to occur 
is a hallmark feature of pre-eclampsia. Further research 
needs to be performed to determine the extent to which AM 
signaling affects trophoblast cells in the process of maternal 
spiral artery remodeling during pregnancy.  
Adrenomedullin Signaling and Cardiovascular Biology 
  AM has been reported to be upregulated in various 
cardiovascular conditions [1, 77, 78] and is a potent 
angiogenic factor as well as a cardioprotective factor [1]. 
Plasma AM increases 2-fold in conditions such as essential 
hypertension, renal failure and congestive heart failure [79, 
80] (Fig. 1). Previous studies with gene-targeted KO mice 
for Adm and Calcrl indicated that AM signaling is important 
for cardiovascular development [22, 30, 33]. Genetic 
reduction of Adm results in enhanced cardiovascular damage 
including increased cardiac hypertrophy in male Adm
+/- mice 
[81] and marked perivascular fibrosis, coronary artery 
intimal hyperplasia and oxidative stress with AngII/high-salt 
treatment [32]. AM protects the heart from hypertrophy and 
fibrosis during cardiovascular stress such as hypertension 
and cardiac hypertrophy, myocardial infarction, heart failure 
and atherosclerosis [82, 83], but the exact mechanisms of 
AM-mediated cardioprotection have not been fully 
elucidated. A comprehensive review of the cardioprotective 
function of AM during hypertension and heart failure has 
recently been provided by several groups [9, 84]. 
  Endothelial dysfunction is characterized by reduced 
endothelium-dependent vascular relaxation which is 
associated with most forms of cardiovascular disease. It is 
partially impacted by reduced nitric oxide and upregulation 
of adhesion molecules to result in a proinflammatory and 
prothrombotic state [85]. Research also suggests that 
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atherosclerosis [86]. One study indicated that Adm and its 
receptor components, Calcrl and Ramps were upregulated in 
the aorta of apolipoprotein E-deficient (ApoE
-/-)
 mice [87]. 
Loss of apoE ultimately results in a mouse model of 
spontaneous atherosclerosis because apoE is important in the 
removal of circulating lipoproteins [88]. When these mice 
were fed an atherogenic diet and treated with AM, the 
appearance of atherosclerotic lesions was reduced [87]. This 
study further indicates that AM may help to protect against 
the progression of atherosclerosis, but the exact mechanism 
for this action remains to be understood. Expression of 
adhesion molecules in LECs [89] as well as liver sinusoidal 
endothelial cells [90] were reduced in response to AM 
treatment. Similar results were seen with VEGF-treated 
HUVECs [91]. Thus, AM may impact endothelial 
dysfunction partially by modulating adhesion molecule 
expression. With respect to endothelium-dependent vascular 
relaxation, AM is known to induce vasodilation which is 
mediated partially by endothelium-derived nitric oxide [92-
96]. Also, in a rat model of sepsis induced by cecal ligation 
and puncture, administration of AM and AM-binding protein 
(AMBP-1 also known as complement factor H) were shown 
to prevent against endothelial cell dysfunction and decreased 
endothelium-dependent vascular relaxation in thoracic aorta 
[97]. These studies implicate AM as having a protective role 
in cardiovascular disease and endothelial dysfunction, but 
further research needs to be performed to investigate how 
AM directly impacts cardiac endothelial cells to regulate 
their function.  
The Role of Adrenomedullin Signaling in Response to 
Injury, Vascular Dysfunction and Wound Healing 
  Endothelial proliferation and angiogenesis are known   
to be impacted by AM signaling. In a hind-limb ischemia 
model, AM promotes endothelial cell proliferation and 
capillary formation and conversely, Adm
+/-  mice showed 
reduced blood flow and capillary development [58]. Other 
whole animal studies using matrigel plugs demonstrated the 
role of AM in vascular regeneration because AM increased 
blood flow and capillary densities through PKA- and PI3K-
dependent pathways [12, 13]. AM also induced tube-
formation of HUVECs cultured on matrigel [14]. Another 
study pertaining to RAMP2 expression also revealed similar 
findings. An aortic ring assay and matrigel plug assay with 
adult  Ramp2
+/-  mice revealed that with decreased Ramp2 
expression there was reduced neovascularization in response 
to growth factor stimulation [18]. Collectively, these studies 
indicate the importance of AM in endothelial cell 
proliferation and angiogenesis in adult mice.  
  AM signaling is known to impact the blood and 
lymphatic vasculature in other physiological processes and 
pathological conditions. In a pathological mouse model of 
subcortical vascular dementia (chronic cerebral hypofusion), 
AM was shown to promote arteriogenesis and angiogenesis 
as well as inhibit oxidative stress and preserve white matter 
in the brain [98]. AM signaling can also induce anti-
apoptotic and anti-inflammatory effects in response to injury. 
In the sinusoidal endothelial cells of the liver, AM helps to 
protect these cells from cold injury during the process of 
cold preservation for a liver transplant by decreasing 
endothelial cell apoptosis and inflammation [90]. 
Conversely, in Adm
+/- and Ramp2
+/- mice there is increased 
apoptosis of the sinusoidal endothelial cells in the liver after 
cold injury [90] further indicating that AM signaling helps to 
regulate apoptosis. Wound healing is an essential 
physiological process that requires angiogenesis and 
lymphangiogenesis for proper healing. Since AM is a known 
angiogenic factor and lymphangiogenic factor [22], it is not 
surprising that AM signaling is necessary in the wound 
healing process. In an ischemia/reperfusion mouse model of 
a pressure ulcer, AM administration reduced the wound area 
and accelerated angiogenesis as well as lymphangiogenesis 
[99]. Also in a wounded HUVEC monolayer, AM promoted 
vascular regeneration via activation of endothelial Akt in a 
PKA- PI3K- dependent manner [12]. Lymphedema is a 
hallmark condition of lymphatic dysfunction resulting in the 
swelling of one or more limbs due to accumulation of 
interstitial fluid. In Balb/C mice with tail lymphedema, AM 
treatment improved lymphedema and increased the number 
of lymphatic and blood vessels near the injury site [11]. 
Taken together, these data indicate that AM is an essential 
component for proper endothelial cell function in both 
physiological and pathological states to regulate apoptosis, 
inflammation, and lymphangiogenesis as well as angio- 
genesis.  
  An important issue to still address is to determine the 
exact role of AM signaling during adulthood by using 
temporal and spatial KO mice for components of the AM 
signaling system to evaluate physiology and function of the 
vascular beds in these mice. Previous studies with genetic 
KO mice for the AM signaling system reveal an enhanced 
impact of AM on lymphatic vascular development relative to 
blood vascular development [22]. It has also been shown that 
the gene expression of AM receptor components, Calcrl and 
Ramp2, are enhanced in LECs compared to BECs [23, 24]. 
Due to these known differences of AM signaling between 
BECs and LECs, it would be interesting to determine 
whether there is also an enhanced effect of AM on the 
lymphatic vasculature in adult physiology and pathology. 
The underlying mechanisms through which AM impacts the 
lymphatic vasculature, blood vasculature as well as the more 
specialized cardiac tissue during adulthood also needs to be 
identified.  
Adrenomedullin Expression in Tumor Progression 
  The AM peptide was initially isolated from a human 
adrenal tumor (pheochromocytoma) due to its platelet cAMP 
elevating activity [78]. Since this discovery almost 20 years 
ago, investigation into the role of AM in tumors has greatly 
expanded. Early studies noticed elevated levels of AM in 
lung and brain tumors [100, 101] and a comprehensive 
survey of human tumor cell lines from lung, breast, brain, 
ovary, colon, and prostate substantiated those reports [102]. 
AM has been implicated in a variety of pro-tumor functions 
including acting as an autocrine growth factor [102-104], 
apoptosis survival factor [15], promoter of tumor cell 234    Current Hypertension Reviews, 2011, Vol. 7, No. 4  Karpinich et al. 
motility and invasion [104-106], and molecular intermediate 
to enhance communication between tumor cells and immune 
cell infiltrates [107]. Furthermore, it has been suggested that 
the presence of AM in tumors may signify a more aggressive 
tumor phenotype due to correlation between Adm gene 
expression and histological tumor grade [104, 108].  
  The mechanism(s) by which Adm gene expression is 
transcriptionally regulated in tumors remains unclear. It is 
likely that AM can be both an autocrine and paracrine factor 
[109] by providing tumor cells a growth advantage in 
addition to acting on surrounding endothelial cells to 
promote proliferation and changes in vessel permeability to 
perhaps facilitate metastasis. Moreover, it has been 
suggested that hypoxia may play a role in AM production [8, 
110]. Tumors often develop hypoxic zones in areas where 
blood flow is inadequate to supply the necessary oxygen 
required for the growing tumor cells. As a result of this 
unfavorable state, hypoxia inducible factor-1 (HIF-1) is 
activated which in turn upregulates a number of genes to 
compensate for the reduced oxygen microenvironment. 
Interestingly, a HIF-1 dependent mechanism was found to 
increase the expression of Adm in hypoxic human tumor cell 
lines [111]. Furthermore, Adm and Calcrl were found to be 
upregulated in microvascular endothelial cells cultured under 
low oxygen conditions [112]. Together, these results show 
that both tumor cells and surrounding endothelial cells are 
responsive to hypoxic conditions and may provide a 
mechanism for elevated AM levels in a tumor setting.  
  Although the precise role of AM in tumor development 
and progression is still unresolved, significant progress has 
been made to better understand how AM affects not only a 
tumor cell, but also the endothelial cells in the surrounding 
microenvironment. Analysis of immunohistochemical 
staining of human ovarian cancer found that in addition to 
tumor cells, AM was also localized to the endothelial cells of 
the surrounding stroma [108]. Furthermore, an in vitro co-
culture system found that HUVECs became activated upon 
exposure to tumor cells and consequently increased 
transcriptional activity of Adm, among other factors [113]. 
Since AM directly impacts endothelial cell proliferation and 
permeability, AM induced modulation of vessels may affect 
the spread of cancer cells to distant sites via  blood or 
lymphatic vasculature. Research groups have been 
performing the in vivo studies necessary to confirm that AM 
promotes tumor progression through its known angiogenic 
properties. Several reports have shown that inhibition of AM 
 
Fig. (2). Adrenomedullin Signaling in Development and Vascular Biology. (A.) Loss of AM signaling causes embryonic lethality due to 
severe edema associated with impaired lymphatic vascular development. (B.) In the adult, AM is an angiogenic, lymphangiogenic, and a 
cardioprotective factor that also regulates vascular permeability and inflammation. Expression of AM is also implicated in pregnancy and 
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action by neutralizing antibodies or AM antagonist AM22-52 
have reduced the growth of tumor xenografts in vivo by 
suppressing vascular development [58, 114, 115].  
  While much of the focus in understanding the process of 
tumor (lymph)angiogenesis has been upon the VEGF protein 
family, the contribution of AM to this process should not be 
underappreciated. Clearly, the studies described above point 
to AM as a valid target for potential cancer therapies 
although more research is necessary. Generation and 
validation of preclinical mouse models that are able to 
rigorously test AM as a target are greatly needed. Since the 
embryonic lethal phenotype of Adm
-/- mice makes studying 
this signaling pathway more complicated, novel genetic 
mouse models (Table 1) using conditional alleles [18, 22, 
116] and vascular endothelium specific Cre animals are a 
starting point for such tumor studies. Furthermore, these 
mouse models will be needed to refine our understanding of 
the metastatic process. Given the knowledge that AM can act 
on both the blood and lymphatic endothelium, a key question 
that remains to be answered is by what mechanisms do tumor 
cells disseminate into the blood and/or lymphatic vessels.  
SUMMARY AND FUTURE DIRECTIONS 
  The use of genetic animal models in the field of AM 
research has produced significant contributions toward 
understanding the biology of this pleiotropic molecule, with 
a renewed appreciation for it's critical regulation of 
endothelial cell function during development and vascular 
diseases. To date, AM has been implicated in lymphatic 
vascular development, in proper functioning of blood and 
lymphatic endothelial cells and in a variety of conditions 
such as pregnancy, cardiovascular disease, and tumor 
progression (Fig. 2). Despite the strides that have been made, 
there is much more to learn regarding the mechanisms 
mediating AM function and regulation. With the generation 
of additional sophisticated molecular biology tools such as 
genetic mouse models, we are poised to refine our current 
knowledge as well as discover other novel roles for this 
peptide and signaling partners in normal and disease 
physiology. 
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